Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016 Read more about Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016
Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy Read more about Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy
Agios to Present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8 Read more about Agios to Present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8
Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones Read more about Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2015 Financial Results on February 18, 2016 Read more about Agios to Webcast Conference Call of Fourth Quarter and Full Year 2015 Financial Results on February 18, 2016
Agios Appoints Steve Hoerter as Chief Commercial Officer Read more about Agios Appoints Steve Hoerter as Chief Commercial Officer
Agios to Present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10 Read more about Agios to Present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10
Agios Outlines Key 2016 Goals and Priorities Read more about Agios Outlines Key 2016 Goals and Priorities
Agios to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11 Read more about Agios to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11
Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Read more about Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients